Fore Biotherapeutics

Based in the United States, Fore Biotherapeutics, fka NovellusDx, operates as a clinical-stage targeted oncology therapeutics developer providing plixorafenib, BRAF-altered cancer programs, and precision oncology drug-development capabilities. The company targeted oncology therapies for patients with cancers driven by BRAF alterations. NovellusDx originally operated as a diagnostics company before pivoting to precision oncology, licensing PLX8394 from Daiichi Sankyo’s Plexxikon unit and rebranding as Fore Biotherapeutics in 2021. The company later advanced plixorafenib through the FORTE Phase 2 basket study. Hinshaw. Based in Philadelphia, United States, Fore Biotherapeutics, fka NovellusDx, provides targeted oncology therapies for patients with cancers driven by BRAF alterations. NovellusDx originally operated as a diagnostics company before pivoting to precision oncology, licensing PLX8394 from Daiichi Sankyo’s Plexxikon unit and rebranding as Fore Biotherapeutics in 2021. The company later advanced plixorafenib through the FORTE Phase 2 basket study. Hinshaw. Fore Biotherapeutics develops targeted oncology medicines for patients with unaddressed tumor mutations, primarily through its lead candidate, plixorafenib. Plixorafenib is an investigational next-generation BRAF inhibitor designed to inhibit a wide range of BRAF gene alterations beyond earlier-generation BRAF inhibitors. The company is evaluating it in the registration-intended global Phase 2 FORTE trial for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600-mutated solid tumors, and advanced solid tumors with BRAF fusions. Its work is supported by oncology drug-development, clinical, regulatory, and business-development teams. The company’s revenue model is not publicly detailed, and plixorafenib remains investigational with no disclosed commercial approval. Fore Biotherapeutics’ website and clinical sources show a development-stage biotechnology model focused on advancing licensed or partnered oncology compounds, clinical trials, and business-development collaborations. The company also states that it considers licensing opportunities and invites potential collaboration discussions.

1. Series D

   Jul 7, 2026

   Amount

   $67M

   Investors

   Locked

2. Series D

   May 22, 2025

   Amount

   $38M

   Investors

   Locked

3. Series D

   Aug 23, 2023

   Amount

   $75M

   Investors

   Locked

4. Series C

   Feb 1, 2022

   Amount

   $4.1M

   Investors

   Locked

5. Series C

   Sep 15, 2021

   Amount

   $1.6M

   Investors

   Locked

6. Series C

   Sep 21, 2020

   Amount

   $57M

   Investors

   Locked